DiaMedica Historical Cash Flow
| DMAC Stock | USD 5.16 0.17 3.19% |
Analysis of DiaMedica Therapeutics cash flow over time is an excellent tool to project DiaMedica Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 28.5 K or Capital Expenditures of 22.8 K as it is a great indicator of DiaMedica Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining DiaMedica Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DiaMedica Therapeutics is a good buy for the upcoming year.
DiaMedica |
About DiaMedica Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in DiaMedica balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which DiaMedica's non-liquid assets can be easily converted into cash.
DiaMedica Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by DiaMedica Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of DiaMedica Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Most accounts from DiaMedica Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Sale Purchase Of Stock is projected to increase significantly based on the last few years of reporting. The current year's Change To Operating Activities is expected to grow to about 376.7 K, whereas Change In Cash is projected to grow to (175.8 K).
DiaMedica Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
DiaMedica Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DiaMedica Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (12.9M) | 3.5M | (2.7M) | 21K | (185K) | (175.8K) | |
| Free Cash Flow | (9.1M) | (9.2M) | (12.3M) | (11.6M) | (18.8M) | (17.8M) | |
| Change In Working Capital | 387K | 1.2M | (461K) | 585K | 93K | 92.2K | |
| Begin Period Cash Flow | 16.8M | 3.9M | 7.4M | 4.7M | 4.7M | 3.2M | |
| Other Cashflows From Financing Activities | 70.0 | 45K | 244K | 0.0 | (18.3M) | (17.4M) | |
| Other Non Cash Items | 49K | 52K | 58K | 53K | (1.2M) | (1.1M) | |
| Capital Expenditures | 50K | 2K | 47K | 81K | 24K | 22.8K | |
| Total Cash From Operating Activities | (9.1M) | (9.2M) | (12.3M) | (11.5M) | (18.7M) | (17.8M) | |
| Net Income | (10.6M) | (12.3M) | (13.6M) | (13.7M) | (19.4M) | (18.4M) | |
| Total Cash From Financing Activities | 70K | 28.8M | 30.1K | (6K) | 36.8M | 38.7M | |
| End Period Cash Flow | 3.9M | 7.4M | 4.7M | 4.7M | 4.5M | 3.5M | |
| Stock Based Compensation | 1.2M | 1.8M | 1.6M | 1.5M | 1.7M | 876.3K | |
| Change To Account Receivables | (43K) | 483K | 210K | 48K | (287K) | (272.7K) | |
| Sale Purchase Of Stock | 3.5M | 21.2M | 75K | 28.9M | 33.2M | 34.8M | |
| Total Cashflows From Investing Activities | (50K) | (3.9M) | (16.1M) | (20.5M) | (18.5M) | (17.6M) | |
| Change To Operating Activities | 731K | (205K) | (81K) | 312K | 358.8K | 376.7K | |
| Change To Netincome | 1.2M | 1.8M | 1.8M | 1.6M | 1.8M | 1.9M | |
| Issuance Of Capital Stock | 7.7M | 28.8M | 29.8M | (18K) | 36.8M | 22.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.